Drug Approval | December 05, 2025
Lupin receives FDA’s tentative approval for Siponimod tablets
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Subscribe To Our Newsletter & Stay Updated
